156 related articles for article (PubMed ID: 22723923)
1. PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).
Toomey JS; Bhatia S; Moon LT; Orchard EA; Tainter KH; Lokitz SJ; Terry T; Mathis JM; Penman AD
PLoS One; 2012; 7(6):e39041. PubMed ID: 22723923
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
[TBL] [Abstract][Full Text] [Related]
4. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
[TBL] [Abstract][Full Text] [Related]
5. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
[TBL] [Abstract][Full Text] [Related]
6. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
7. Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133).
Liu Y; Yue F; Tang R; Tao G; Pan X; Zhu L; Kung HF; Chan P
Neurosci Bull; 2014 Jun; 30(3):409-16. PubMed ID: 24061965
[TBL] [Abstract][Full Text] [Related]
8. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
9. Motor behavior correlates with striatal [¹⁸F]-DOPA uptake in MPTP-lesioned primates.
Kortekaas R; Eshuis SA; Andringa G; Cools AR; Leenders KL
Neurochem Int; 2013 Mar; 62(4):349-53. PubMed ID: 23357476
[TBL] [Abstract][Full Text] [Related]
10. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
11. Quantitative study of
Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
13. Validation of nigrostriatal positron emission tomography measures: critical limits.
Karimi M; Tian L; Brown CA; Flores HP; Loftin SK; Videen TO; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Mar; 73(3):390-6. PubMed ID: 23423933
[TBL] [Abstract][Full Text] [Related]
14. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
15. [
Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
[TBL] [Abstract][Full Text] [Related]
16. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
[TBL] [Abstract][Full Text] [Related]
17. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
18. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
[TBL] [Abstract][Full Text] [Related]
19. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
